JP2024507788A - Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物 - Google Patents

Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物 Download PDF

Info

Publication number
JP2024507788A
JP2024507788A JP2023548941A JP2023548941A JP2024507788A JP 2024507788 A JP2024507788 A JP 2024507788A JP 2023548941 A JP2023548941 A JP 2023548941A JP 2023548941 A JP2023548941 A JP 2023548941A JP 2024507788 A JP2024507788 A JP 2024507788A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
hiv
compound
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548941A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024507788A5 (https=
Inventor
ハーティング，ティモシー・ジョン
マッコーリー，ジョン・エー．
ユウ，タオ
ジャン，ヨンリアン
Original Assignee
メルク・シャープ・アンド・ドーム・エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルク・シャープ・アンド・ドーム・エルエルシー filed Critical メルク・シャープ・アンド・ドーム・エルエルシー
Publication of JP2024507788A publication Critical patent/JP2024507788A/ja
Publication of JP2024507788A5 publication Critical patent/JP2024507788A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
JP2023548941A 2021-02-16 2022-02-14 Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物 Pending JP2024507788A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
US63/149,927 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (2)

Publication Number Publication Date
JP2024507788A true JP2024507788A (ja) 2024-02-21
JP2024507788A5 JP2024507788A5 (https=) 2025-02-13

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548941A Pending JP2024507788A (ja) 2021-02-16 2022-02-14 Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物

Country Status (11)

Country Link
US (1) US11958864B2 (https=)
EP (1) EP4294813B1 (https=)
JP (1) JP2024507788A (https=)
KR (1) KR20230147131A (https=)
CN (1) CN117083282A (https=)
AR (1) AR124868A1 (https=)
CA (1) CA3208396A1 (https=)
ES (1) ES3048138T3 (https=)
MX (1) MX2023009445A (https=)
TW (1) TW202246286A (https=)
WO (1) WO2022177840A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4704976A1 (en) * 2023-04-28 2026-03-11 Merck Sharp & Dohme LLC Delivery devices for anti-hiv compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP2011529071A (ja) * 2008-07-25 2011-12-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
JP2011529070A (ja) * 2008-07-25 2011-12-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
WO2012039414A1 (ja) * 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
JP2019536791A (ja) * 2016-12-02 2019-12-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017113288A1 (en) * 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011812A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP2011529071A (ja) * 2008-07-25 2011-12-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
JP2011529070A (ja) * 2008-07-25 2011-12-01 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 化合物
WO2012039414A1 (ja) * 2010-09-24 2012-03-29 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体のプロドラッグ
JP2019536791A (ja) * 2016-12-02 2019-12-19 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物
WO2018140368A1 (en) * 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors

Also Published As

Publication number Publication date
AU2022223241A1 (en) 2023-08-24
EP4294813A1 (en) 2023-12-27
AR124868A1 (es) 2023-05-10
US20220259227A1 (en) 2022-08-18
KR20230147131A (ko) 2023-10-20
MX2023009445A (es) 2023-08-25
US11958864B2 (en) 2024-04-16
TW202246286A (zh) 2022-12-01
WO2022177840A1 (en) 2022-08-25
ES3048138T3 (en) 2025-12-09
EP4294813B1 (en) 2025-09-10
CA3208396A1 (en) 2022-08-25
CN117083282A (zh) 2023-11-17

Similar Documents

Publication Publication Date Title
JP2024507788A (ja) Ｈｉｖインテグラーゼ阻害剤として有用な四環式複素環化合物
EP3752144B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
JP6081662B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
TWI656122B (zh) 作為ｈｉｖ整合酶抑制劑之稠合三環雜環化合物
US10624912B2 (en) Spirocyclic Pyridotriazine Derivatives useful as HIV integrase inhibitors
US11884683B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
JP2021522254A (ja) Ｈｉｖインテグラーゼ阻害剤として有用な三環式複素環化合物
US10934312B2 (en) Tricyclic heterocycle compounds useful as HIV integrase inhibitors
JP2019500387A (ja) Ｈｉｖインテグラーゼ阻害剤としての縮合三環式複素環化合物
WO2016187788A1 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10786488B2 (en) Substituted quinolizine derivatives useful as HIV integrase inhibitors
RU2851203C2 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
AU2022223241B2 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20210115044A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250204

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251113

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260410